![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1305188
¼¼°èÀÇ HIV/AIDS Áø´Ü ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)Global HIV/AIDS Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030 |
HIV/AIDS Áø´Ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2022³â 62¾ï 2,000¸¸ ´Þ·¯¿¡¼ 2030³â 137¾ï 5,000¸¸ ´Þ·¯¿¡ °¡±î¿î ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2023-2030³â Á¶»ç ±â°£ µ¿¾È 10.42%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
HIV/AIDS Áø´ÜÀº Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV)ÀÇ Á¸À縦 °¨ÁöÇϰí ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(AIDS)ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ »ç¿ëµÇ´Â °Ë»ç ¹× ¹æ¹ýÀ» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü¿¡´Â HIV Ç×ü ¹× Ç׿ø, ¹ÙÀÌ·¯½º ¾ç, CD4 T ¼¼Æ÷ ¼ö¸¦ °¨ÁöÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ½ÇÇè½Ç °Ë»ç ¹× ÇöÀå °Ë»ç(POC) Àåºñ°¡ Æ÷ÇԵ˴ϴÙ.
HIV/AIDS ¿¹¹æ ¹× Ä¡·áÀÇ Å« ÁøÀü¿¡µµ ºÒ±¸Çϰí, ÀÌ Áúº´Àº ¿©ÀüÈ÷ ¼¼°è º¸°ÇÀÇ Å« µµÀüÀÌ µÇ°í ÀÖÀ¸¸ç, 2019³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î ¾à 3,800¸¸ ¸íÀÌ HIV/AIDS¸¦ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù(WHO º¸°í¼). ÀÌ·¯ÇÑ HIV/AIDSÀÇ ³ôÀº À¯º´·üÀº Áúº´À» Á¤È®ÇÏ°Ô °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â Áø´Ü¾à¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÁßÀú¼Òµæ ±¹°¡¿¡¼ ÀÇ·á ½Ã½ºÅÛÀÌ °³¼±µÇ°í Á¢±Ù¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó HIV/AIDS °Ë»ç¸¦ ¹Þ´Â »ç¶÷µéÀÌ ´Ã¾î³ª°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àú·ÅÇϰí Á¤È®ÇÏ¸ç »ç¿ëÇϱ⠽¬¿î Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î HIV/AIDS¿¡ ´ëÇÑ º¸´Ù ¹Î°¨ÇÏ°í Æ¯ÀÌÀûÀÎ °Ë»ç¹ýÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, »õ·Î¿î POC Àåºñ´Â ³ôÀº Á¤È®µµ¿Í ºü¸¥ °á°ú¸¦ Á¦°øÇÏ¿© Á¶±â Áø´Ü ¹× Á¶±â Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϸç, HIV/AIDS ÀÚ°¡ °Ë»ç´Â ƯÈ÷ HIV/AIDSÀÇ À¯º´·üÀÌ ³ôÀº ±¹°¡¿¡¼ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÚ°¡ °Ë»ç´Â ÀÇ·á ¼ºñ½º Á¦°øÀÚ¸¦ ÅëÇÏÁö ¾Ê°í Áý¿¡¼ ÇÁ¶óÀ̹ö½Ã¸¦ ÁöŰ¸é¼ ½º½º·Î °Ë»çÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÚ°¡ °Ë»ç ŰƮ´Â Á¤È®Çϰí Àú·ÅÇÏ¸ç »ç¿ëÇϱ⠽±±â ¶§¹®¿¡ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ±¹Á¦±â±¸´Â HIV/AIDSÀÇ Áø´Ü°ú Ä¡·á¸¦ °³¼±Çϱâ À§ÇÑ ³ë·Â¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â »õ·Î¿î Áø´Ü ±â¼ú ¿¬±¸ ¹× °³¹ß ÀÚ±Ý Áö¿ø, °Ë»ç ¹× Ä¡·á Á¢±Ù¼º Çâ»óÀ» À§ÇÑ ÇÁ·Î±×·¥ µîÀÌ Æ÷ÇԵ˴ϴÙ.
ÀÌ Á¶»ç º¸°í¼´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â HIV/AIDS Áø´Ü ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖÀ¸¸ç, HIV/AIDS Áø´Ü »ê¾÷ÀÇ ¼ºÀå°ú Ãß¼¼´ÂÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
ÀÌ ¼½¼Ç¿¡¼´Â ±¹°¡º°, Áö¿ªº° ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© °¢ Á¦Ç° ¹× ¼ºñ½ºÀÇ Å¸°ÙÃþÀ» ÆÄ¾ÇÇÏ¿© ÇâÈÄ ºñÁö´Ï½º ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖµµ·Ï µµ¿Íµå¸³´Ï´Ù.
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ HIV/AIDS Áø´Ü ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
*Âü°í : ±â¾÷ °³¿ä¿¡¼ À繫 ³»¿ëÀ̳ª ÃÖ±ÙÀÇ µ¿ÇâÀº ºñ°ø°³ ±â¾÷ÀÇ °æ¿ì ÀÔ¼ö °¡´É ¿©ºÎ¿¡ µû¶ó ´Þ¶óÁö°Å³ª Á¦°øµÇÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.
ksm 23.08.22The global demand for HIV/AIDS Diagnostics Market is presumed to reach the market size of nearly USD 13.75 BN by 2030 from USD 6.22 BN in 2022 with a CAGR of 10.42% under the study period 2023 - 2030.
HIV/AIDS diagnostics refer to the tests and methods used to detect the presence of the human immunodeficiency virus (HIV) and monitor the progression of acquired immunodeficiency syndrome (AIDS). These diagnostics include various laboratory tests and point-of-care (POC) devices that can detect HIV antibodies or antigens, viral load, and CD4 T-cell count.
Despite significant progress in HIV/AIDS prevention and treatment, the disease remains a major global health challenge. There were an estimated 38 million people living with HIV/AIDS worldwide in 2019 (WHO report). This high prevalence of HIV/AIDS is driving the demand for diagnostics that can accurately detect and monitor the disease. As healthcare systems improve and become more accessible in low- and middle-income countries, more people are being tested for HIV/AIDS. This is leading to a greater demand for affordable, accurate, and easy-to-use diagnostic tests. Recent advancements in diagnostic technology have led to the development of more sensitive and specific tests for HIV/AIDS. For example, new POC devices can deliver rapid results with high accuracy, allowing for earlier diagnosis and treatment. Self-testing for HIV/AIDS is becoming more popular, particularly in countries with high HIV/AIDS prevalence. Self-testing allows individuals to test themselves in the privacy of their own home, without the need for a healthcare provider. This has scaled up self-testing kits demand as they are accurate, affordable, and easy to use. Governments and international organizations are investing in initiatives to improve HIV/AIDS diagnosis and treatment. This includes funding for research and development of new diagnostic technologies, as well as programs to increase access to testing and treatment.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hiv/aids diagnostics. The growth and trends of hiv/aids diagnostics industry provide a holistic approach to this study.
This section of the hiv/aids diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the HIV/AIDS Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the hiv/aids diagnostics market include Hologic Inc., Abbott, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., OraSure Technologies Inc., Siemens Healthcare GmbH, Chembio Diagnostics Inc., Danaher Corporation, Becton, Dickinson and Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies